Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Special drug use observational study of Beovu for diabetic macular edema
jRCT2031220323Completed
- Sponsor
- Novartis
- Start
- Sep 2022
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of brolucizumab in diabetic macular edema (DME), sponsored by Novartis. Primary endpoints: Ocular safety specifications adverse events, Ocular adverse events in treated eyes and 1 more. Started Sep 2022; status: completed.
02
Drugs
brolucizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on jRCT2031220323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220323.